Multinu F, Ducie JA, Eriksson AGZ, et al. - Individuals with stage IIIC endometrial cancer (EC; n = 104 [48 lymphadenectomy {LND}, 56 sentinel lymph node {SLN}]) treated at two institutions were retrospectively recognized in order to contrast survival and progression outcomes between two nodal evaluation strategies in individuals with nonbulky stage IIIC EC. The use of chemoradiotherapy was comparable in the two cohorts (LND vs SLN cohort), however, the use of chemotherapy alone or radiotherapy alone varied. However, evidence of greater risk of cause-specific death and lower risk of para-aortic progression for the LND group was discovered, the relations did not reach statistical importance. Between the groups, the risk of progression was not significantly distinct. High-risk tumor features and nonendometrioid types were independently related to lower cause-specific survival and progression-free survival in parsimonious multivariable models. In conclusion, the use of the SLN algorithm with restricted nodal dissection does not jeopardize survival in comparison with LND, in individuals with EC with nonbulky positive lymph nodes. Moreover, the most robust determinants of prognosis are aggressive pathologic characteristics of the primary tumor.